Zobrazeno 1 - 10
of 75
pro vyhledávání: '"David M. Markusic"'
B cell focused transient immune suppression protocol for efficient AAV readministration to the liver
Autor:
Jyoti Rana, Roland W. Herzog, Maite Muñoz-Melero, Kentaro Yamada, Sandeep R.P. Kumar, Anh K. Lam, David M. Markusic, Dongsheng Duan, Cox Terhorst, Barry J. Byrne, Manuela Corti, Moanaro Biswas
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 32, Iss 1, Pp 101216- (2024)
Adeno-associated virus (AAV) vectors are used for correcting multiple genetic disorders. Although the goal is to achieve lifelong correction with a single vector administration, the ability to redose would enable the extension of therapy in cases in
Externí odkaz:
https://doaj.org/article/dbfee83096ee41878357669ddf1b4522
Autor:
Miguel Gonzalez-Visiedo, Roland W. Herzog, Maite Munoz-Melero, Sophia A. Blessinger, Joan M. Cook-Mills, Henry Daniell, David M. Markusic
Publikováno v:
Viruses, Vol 16, Iss 7, p 1125 (2024)
Food allergy (FA) is estimated to impact up to 10% of the population and is a growing health concern. FA results from a failure in the mucosal immune system to establish or maintain immunological tolerance to innocuous dietary antigens, IgE productio
Externí odkaz:
https://doaj.org/article/9a57a1000a05483fb8e70f3d617faad2
Autor:
Miguel Gonzalez-Visiedo, Xin Li, Maite Munoz-Melero, Michael D. Kulis, Henry Daniell, David M. Markusic
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 26, Iss , Pp 309-322 (2022)
Immunotherapies for patients with food allergy have shown some success in limiting allergic responses. However, these approaches require lengthy protocols with repeated allergen dosing and patients can relapse following discontinuation of treatment.
Externí odkaz:
https://doaj.org/article/5eb6814f4187470190ad8278d7d9c90c
Autor:
Sandeep R.P. Kumar, Jun Xie, Shilang Hu, Jihye Ko, Qifeng Huang, Harrison C. Brown, Alok Srivastava, David M. Markusic, Christopher B. Doering, H. Trent Spencer, Arun Srivastava, Guangping Gao, Roland W. Herzog
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 23, Iss , Pp 98-107 (2021)
Hepatic gene transfer with adeno-associated viral (AAV) vectors shows much promise for the treatment of the X-linked bleeding disorder hemophilia B in multiple clinical trials. In an effort to further innovate this approach and to introduce alternati
Externí odkaz:
https://doaj.org/article/c8c0531282d4473082e53448b9e6d260
Autor:
Ashley T. Martino, David M. Markusic
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 17, Iss , Pp 198-208 (2020)
Early preclinical studies in rodents and other species did not reveal that vector or transgene immunity would present a significant hurdle for sustained gene expression. While there was early evidence of mild immune responses to adeno-associated viru
Externí odkaz:
https://doaj.org/article/d05848937dce484ea4c82d56b45af200
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Hemophilia A is an inherited coagulation disorder resulting in the loss of functional clotting factor VIII (FVIII). Presently, the most effective treatment is prophylactic protein replacement therapy. However, this requires frequent life-long intrave
Externí odkaz:
https://doaj.org/article/74888e59bb5d42edb4e4e2be3011cf19
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 5, Iss C, Pp 142-152 (2017)
Multiple independent adeno-associated virus (AAV) gene therapy clinical trials for hemophilia B, utilizing different AAV serotypes, have reported a vector dose-dependent loss of circulating factor IX (FIX) protein associated with capsid-specific CD8+
Externí odkaz:
https://doaj.org/article/8cb46ba869564c8980d91cf54bc5ee63
Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models
Autor:
David M. Markusic, Timothy C. Nichols, Elizabeth P. Merricks, Brett Palaschak, Irene Zolotukhin, Damien Marsic, Sergei Zolotukhin, Arun Srivastava, Roland W. Herzog
Publikováno v:
Journal of Translational Medicine, Vol 15, Iss 1, Pp 1-11 (2017)
Abstract Background Adeno-associated virus (AAV) gene therapy vectors have shown the best outcomes in human clinical studies for the treatment of genetic diseases such as hemophilia. However, these pivotal investigations have also identified several
Externí odkaz:
https://doaj.org/article/f621a02988f943ae9689ad35be3ac336
Autor:
David M. Markusic, Alok Srivastava, Shilang Hu, Qifeng Huang, Roland W. Herzog, Harrison C. Brown, Christopher B. Doering, Guangping Gao, Jun Xie, Arun Srivastava, Jihye Ko, Sandeep R. P. Kumar, H. Trent Spencer
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 23, Iss, Pp 98-107 (2021)
Molecular Therapy: Methods & Clinical Development, Vol 23, Iss, Pp 98-107 (2021)
Hepatic gene transfer with adeno-associated viral (AAV) vectors shows much promise for the treatment of the X-linked bleeding disorder hemophilia B in multiple clinical trials. In an effort to further innovate this approach and to introduce alternati
Publikováno v:
Cellular immunology. 382
Loss of oral tolerance (OT) to food antigens results in food allergies. One component of achieving OT is the symbiotic microorganisms living in the gut (microbiota). The composition of the microbiota can drive either pro-tolerogenic or pro-inflammato